openPR Logo
Press release

Global Oncology Drugs Market - Competitive Analysis

04-11-2018 11:25 AM CET | Health & Medicine

Press release from: Pharmaceutical Report

Oncology drugs and medications have become a blooming business for players in the pharmaceutical industry. Major pharmaceutical companies are focused on manufacturing and development of oncology drug. Market players have oncology drugs in pipeline, which are expected to be in the market as potential medications in near future. Also, the global oncology market is expected to gain a significant traction with the increasing prevalence of cancer. According to the National Cancer Institute, cancer is among the leading causes of death worldwide, which accounted for around 14 million new cases and 8.2 million cancer-related deaths in 2012. The number of new cancer cases is projected to rise to 22 million in near future. The major competitors are focused on developing efficient treatment for specific type of cancer which is expected to be a prominent factor to augment the global oncology drugs market.

Major manufacturers in the oncology drugs market include:

Johnson & Johnson
Bristol-Meyers Squibb
Eli Lily
Merck & Co.

Get The Holistic SAMPLE With Research Methodology:

Top 5 company described for competitive analysis in detail:

Roche is a world leader in oncology, which is engaged in developing new approaches for advanced cancer treatment. Roche operates in two segments, which includes pharmaceuticals and diagnostics with annual sales of US$ 39.1 Bn and US$ 11.5 Bn respectively. Roche is at the forefront of cancer immunotherapy with ten investigational drug candidates currently in the clinical development phase. In 2016, the company entered into 10 new clinical collaboration agreements to explore drug combinations for maximizing therapeutic benefits and develop the lead immunotherapy drug. The company has set up imCORE, a network of 21 academic institutions working with Roche to advance research into cancer immunotherapies, thus contributing to enhance the global oncology drugs market in the near future.

Johnson and Johnson operates in three business segments namely consumer, pharmaceutical and medical devices. The business of Johnson & Johnson is conducted by more than 230 operating companies located in 60 countries worldwide. In 2016, the company has invested around US$ 9.1 Bn in research and development activities. Janssen, the pharmaceutical division of J&J registered the oncology drug sales of around US$ 5.9 Bn among the total pharmaceutical therapeutic area sales. Janssen is focused on strategic collaborations for the development of cancer therapeutics, which in turn favors the oncology drugs market. For instance, in November, 2017, Janssen collaborated with Zymeworks, Inc. to develop six bispecific antibodies based on Azymetric and Effector Function Enhancement and Control Technology (EFECT) platforms for research, development, and commercialization with a potential to generate US$ 1.5 Bn. High sales of IMBRUVICA (ibrutinib) and DARZALEX (daratumumab) were due to increasing patient uptake, additional country launches, and additional indications, which contributed to the growth of oncology drugs.

Pfizer, Inc. develops oncology therapies that provide maximum efficacy while minimizing adverse effects on the patient. The current portfolio of oncology drugs covers a range of cancers. The company studies these therapies alone and in combination with other treatments to improve the lives of cancer patients. Pfizer’s overall strategy is anchored on innovation for developing new medicines and vaccines through collaborations and business relationships which is expected to bolster the oncology drugs market. For instance, Pfizer partnered with Merck KGaA for building a strong portfolio in immuno-oncology, Biolnvent International AB to develop antibodies to advance the novel technology platform of cancer vaccine as well as business relationship with IBM Watson for drug discovery by identifying potential new targets and combination therapies in immune-oncology.

Novartis’s aims to develop approaches for extending the lives of people suffering from cancer, by adopting the strategy to use science-based innovation for delivering better patient outcomes in growing areas of healthcare. Novartis operates in two business segments namely Novartis Oncology and Novartis Pharmaceuticals, which together form Innovative Medicines Division. The Novartis Oncology segment contributed around 39% of its net sales, it was valued around US$ 12.8 Bn. Increase in revenue is attributed to the strong performance for oncology products Tafinlar + Mekinist, a combination therapy for advanced melanoma, and Jakavi, for blood cancers. Novartis is leading provider of cancer treatments, following the acquisition of oncology products from GlaxoSmithKline in 2015. In 2016, the company collaborated with Surface Oncology to bolster the cancer immunotherapy pipeline that will provide access to four preclinical programs. Also, with a licensing agreement with Xencor, it plans to co-develop two bispecific antibodies designed to target acute myeloid leukemia and B-cell malignancies, thereby aiding the growth of oncology drugs market.

Get Table Of Content:

Sanofi operates through two business segments namely pharmaceuticals and vaccines. Sanofi gains insights through its network of collaborations with biotech companies such as Immunogen and Evotec, academic cancer centers such as Institut Gustave Roussy, Institut Curie, and the Dana Farber Cancer Institute, enabling superior use of software, analytics, and new technology, which helps to increase its productivity, maximize return on R&D investment, and accelerate the development of new products. Sanofi Oncology has a large number of collaborations and alliances to support its R&D portfolio. In 2015, Sanofi collaborated with Regeneron focusing on cancer immunotherapy to generate high value development candidates in the emerging field of immuno-oncology and to accelerate its development pipeline in the oncology drugs market. In 2016, the company entered into a collaboration with Innate Pharma to develop innovative bispecific antibody formats engaging natural killer (NK) cells to kill tumor cells. Also, it collaborated with Warp Drive Bio to develop drugs targeting human oncogenes, thus accelerating the innovations for oncology drugs.

Novel and targeted oncology drugs manufactured by the major competitors in oncology drug market are geared towards the treatment of specific type of cancer with premium prices, without generic competition from the competitors, as these biologic treatments have an enhanced patent protection. Strategic collaborations and rise in research and development is the basic approach adopted by the manufacturers, as it helps to develop and access knowledge and increase the understanding in new areas of science, thereby accelerating the global oncology drugs market.

The major strategic collaborations included in the competitive analysis include:
Sanofi and Regeneron collaborated to develop REGN2810, with an overall expenditure of US$ 325 million each towards developing the therapy currently in the Phase I
Bristol-Myers Squibb (BMS) and CytomX Therapeutics collaborated to develop four target cancer therapies using CytomX’s Probody drug discovery platform. The collaboration would provide CytomX with a net US$ 1.2 Bn.

Buy This Exclusive Report:

About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:
Coherent Market Insights
1001 4th Ave,
Seattle, WA 98154
Tel: +1-206-701-6702
Visit our news Website:

This release was published on openPR.

Permanent link to this press release:

Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Global Oncology Drugs Market - Competitive Analysis here

News-ID: 1011410 • Views: 277

More Releases from Pharmaceutical Report

Batten Disease Treatment Market - Global Industry Insights, Trends, Outlook, and …
Batten disease is a rare, inherent, and fatal autosomal recessive neural disorder that begins in the childhood but may take a few years to show symptoms. Batten disease is one of the approximately 50 diseases that fall under the category of lysosome shortage disorders. The batten disease also referred as Neuronal ceroid Lipofuscinoses (NCLs), which is a class of life-limiting genetic neurogenerative diseases that are caused due to abnormality of
Opioids – Reducing body pain but increasing pain for regulatory authorities
Opioids are drugs primarily prescribed for pain management and treatment of diarrhea and cough. Opioid drugs are of two types namely, agonist and antagonist. Codeine, Fentanyl, Meperidine, Methadone, Morphine, Hydrocodone, Diphenoxylate, Hydromorphone, Methylphenidate, Oxycodone, and Oxymorphone are classified as agonists, while Buprenorphine, Naloxone, Naltrexone, Methylnaltrexone, and Nalbuphine are classified as antagonists. Due to easy availability of opioids, these drugs are rampantly overused globally and the situation is more critical in
Human Chorionic Gonadotropin (HCG) Market to Rear Excessive Growth During 2016 …
Human chorionic gonadotropin hormone (HCG) is a hormone secreted by the placenta after implantation of a fertilized zygote in the uterus. The hormone also supports normal development of an egg and helps in the stimulation of egg release from the ovary. The HCG is mainly used to induce ovulation in the women under infertility treatment. It is also used among males mostly to increase the sperm count and in young
Medical Waste Management Market, By Services, and By Techniques - Global Industr …
Healthcare activities generates a lot of waste, especially from the frequently used consumables, which are harmful for in-patients and healthy population. Medical waste includes waste generated within research centers and health-care facilities for example, sharps waste, infectious waste, pathological waste, pharmaceutical waste, chemical waste, and radioactive waste. The waste product that are generated by the healthcare activities have higher potential to spread infection and injuries. Inadequate or incorrect handling of

All 5 Releases

More Releases for Novartis

Rydapt Market 2020 Clinical Analysis – Novartis
Global Rydapt Market Growth 2020-2025 The report will make detailed analysis mainly on in-depth research on the development environment, Market size, development trend, operation situation and future development trend of Rydapt Market on the basis of stating current situation of the industry in 2020. This is a latest report, covering the current COVID-19 impact on the market. The pandemic of Coronavirus (COVID-19) has affected every aspect of life globally. This has brought
Global Octreotide Market 2019 - Novartis, Sun Pharmaceutical, Chengdu Tiantaisha …
This new report by Eon Market Research, titled “Global Octreotide Market 2019 Research Report, 2015 – 2025” offers a comprehensive analysis of Octreotide industry at a global as well as regional and country level. Key facts analyzed in this report include the Octreotide market size by players, regions, product types and end industries, history data 2014-2018 and forecast data 2019-2025. This report primarily focuses on the study of the competitive
Biologic Therapeutics Market - Qualitative Insights 2025 | Novartis Global, Smit …
Global Biologic Therapeutics Market: Snapshot The branch of science that deals with manufacturing medicines and pharmaceutical products based on biological origins is called biological therapeutics. Any pharmaceutical drug product manufactured from semi-synthesized and biological sources is included under this field. Owing to rapid advances experienced by this sector, a distinct biologic therapeutics market has formed. This market is mainly being driven by a rising demand for better healthcare treatments occurring all
Ewing Sarcoma Therapeutics - Pipeline Analysis Celgene, Novartis, Pfizer, MacroG …
Ewing sarcoma pipeline comprises approximately 29 drug candidates in different stages of development. Ewing sarcoma is a condition in which formation of cancer or tumor takes place in bones and soft tissues. The symptoms associated with Ewing sarcoma include pain as well as swelling in the chest, back, legs, pelvis and arms, lumps in arms, bone fracture, weight loss, loss of appetite, fatigue, malaise, etc. Download free report Sample at: *Major companies
Nilotinib Market Report 2018 – 2023: Novartis
The Study Paper in this Global Nilotinib Market includes Novartis. Get Free Sample Brochure of Nilotinib Market spread across [142 pages] @ Unbiased perspective on intangible aspects such as key challenges, threats, new entrants as well as strengths and weaknesses of the prominent vendors too are
Sarcoma Drugs Market – Qualitative Benefits 2028 | Novartis, Amgen, Eli Lilly
Global Sarcoma Drugs Market: Overview A sarcoma, a rare form of cancer, differs from the more common carcinomas in one major way – they occur in a different type of tissue known as connective tissue. Those are essentially cells that support or connect other types of tissue in the human body. Sarcoma is highly common in muscles, bones, fats, nerves, cartilage, and blood vessels in one’s arms and legs. They can,